Clinical Trial: Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07517575) titled 'Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis' on Dec. 30, 2025.

Brief Summary: The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged >2 and 2 and <18 years.

Study Start Date: March 17, 2023

Study Type: INTERVENTIONAL

Condition: Juvenile Idiopathic Arthritis

Intervention: DRUG: OKZ q4w

Subcutaneous (SC) injections of OKZ every 4 weeks; Olokizumab is a sterile solution for subcutaneous injection

DRUG: OKZ q4w

SC injections of OKZ 48 mg every 4 weeks; Olokizumab is a...